PLK1 and neoplasm: Dr. Zeming Chen et al. developed liposome-templated hydrogel nanoparticles (LHNPs) combined with minicircle DNA technology to deliver a CRISPR-Cas9 system targeting Plk1 (polo-like kinase 1), which effectively repressed tumor growth and improved the survival rate of tumor-bearing mice [58].